Detalhe da pesquisa
1.
The PDE4 inhibitor tanimilast shows distinct immunomodulatory properties associated with a type 2 endotype and CD141 upregulation.
J Transl Med
; 20(1): 203, 2022 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35538539
2.
The PDE4 Inhibitor Tanimilast Restrains the Tissue-Damaging Properties of Human Neutrophils.
Int J Mol Sci
; 23(9)2022 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35563373
3.
The PDE4 inhibitor CHF6001 affects keratinocyte proliferation via cellular redox pathways.
Arch Biochem Biophys
; 685: 108355, 2020 05 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32268137
4.
Anti-inflammatory effects of the phosphodiesterase type 4 inhibitor CHF6001 on bronchoalveolar lavage lymphocytes from asthma patients.
Cytokine
; 113: 68-73, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29934047
5.
The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients.
Cytokine
; 123: 154739, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31319374
6.
The PDE4 inhibitor CHF-6001 and LAMAs inhibit bronchoconstriction-induced remodeling in lung slices.
Am J Physiol Lung Cell Mol Physiol
; 313(3): L507-L515, 2017 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28596292
7.
In vitro and in vivo characterization of poractant alfa supplemented with budesonide for safe and effective intratracheal administration.
Pediatr Res
; 82(6): 1056-1063, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28723887
8.
Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.
Circulation
; 131(22): 1981-8, 2015 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-25948538
9.
Prevention of Atrial Fibrillation in High-risk Patients Undergoing Lung Cancer Surgery: The PRESAGE Trial.
Ann Surg
; 264(2): 244-51, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26764872
10.
CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration--in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window.
J Pharmacol Exp Ther
; 352(3): 568-78, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25576073
11.
CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration.
J Pharmacol Exp Ther
; 352(3): 559-67, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25576075
12.
Monitoring inflammation and airway remodeling by fluorescence molecular tomography in a chronic asthma model.
J Transl Med
; 13: 336, 2015 Oct 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-26496719
13.
Enlightened Mannhemia haemolytica lung inflammation in bovinized mice.
Vet Res
; 45: 8, 2014 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-24460618
14.
CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder.
Front Pharmacol
; 15: 1343941, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38549671
15.
Discovery, Multiparametric Optimization, and Solid-State Driven Identification of CHF-6550, a Novel Soft Dual Pharmacology Muscarinic Antagonist and ß2 Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases.
J Med Chem
; 2024 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38857426
16.
Receptor for advanced glycation end products contributes to postnatal pulmonary development and adult lung maintenance program in mice.
Am J Respir Cell Mol Biol
; 48(2): 164-71, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23144333
17.
Harnessing the translational power of bleomycin model: new insights to guide drug discovery for idiopathic pulmonary fibrosis.
Front Pharmacol
; 14: 1303646, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38099140
18.
Time-course transcriptome analysis of a double challenge bleomycin-induced lung fibrosis rat model uncovers ECM homoeostasis-related translationally relevant genes.
BMJ Open Respir Res
; 10(1)2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37730279
19.
Discovery of a Potent, Selective, and Orally Bioavailable Tool Compound for Probing the Role of Lysophosphatidic Acid Type 2 Receptor Antagonists in Fibrotic Disorders.
J Med Chem
; 66(8): 5622-5656, 2023 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37017110
20.
Optimization of M3 Antagonist-PDE4 Inhibitor (MAPI) Dual Pharmacology Molecules for the Treatment of COPD.
J Med Chem
; 66(16): 11476-11497, 2023 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37561958